Month 1 Increased energy Improved stamina Deeper, more restful sleep Month 2 Improved skin Reduced wrinkles Stronger nails and hair Increased metabolism Month 3 Enhanced sex drive and performance Improved mental focus Improved joint health Month 4 Continued weight reduction Improved skin elasticity Increased lean muscle mass Month 5 Noticeably fuller, healthier hair Reduced appearance of wrinkles Better skin tone Continued reduction in belly fat Month 6 5-10% reduction in body fat (without exercise/diet) 10% increase in lean muscle mass Improved vitality due to organ regrowth If you are interested in any of the peptides we offer at Envizion Medical, check out www.envizionmedical.com or call 813-279-2211!

Discussion Treatment with antipsychotic drugs such as olanzapine can result in severe metabolic consequences such as hyperglycemia, dysregulated lipid metabolism, weight gain and the development of type 2 diabetes, in a population that suffers from premature cardiovascular mortality ( GLP1 receptor agonists such as liraglutide have proven to be effective pharmacological tools to reduce weight gain in individuals treated with antipsychotics [( A potential confounder to the current experiments is that we cannot account for other hormones that might be stimulated by oral glucose and preserved by inhibition of DPPiv such as gastric inhibitory peptide (GIP), an incretin hormone and substrate of DPPiv ( Treatment with GLP1 receptor agonists are effective and generally well-tolerated but they can be limited by the requirement of repeated injections, dose escalation, nausea, and injection-site reactions ( Findings from the current investigation provide proof of principle that increasing endogenous levels of GLP1 can provide therapeutic benefit in alleviating the metabolic side effects of olanzapine

Together, these two components may provide synergistic benefits in certain treatment contexts
Recommended Expanding focus for cardiologists The diabetic patient and cardiovascular outcomesIntroduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes Prof